JP2025503661A5 - - Google Patents

Info

Publication number
JP2025503661A5
JP2025503661A5 JP2024541657A JP2024541657A JP2025503661A5 JP 2025503661 A5 JP2025503661 A5 JP 2025503661A5 JP 2024541657 A JP2024541657 A JP 2024541657A JP 2024541657 A JP2024541657 A JP 2024541657A JP 2025503661 A5 JP2025503661 A5 JP 2025503661A5
Authority
JP
Japan
Prior art keywords
prodrugs
solvates
stereoisomers
mixtures
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503661A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/050255 external-priority patent/WO2023131690A1/en
Publication of JP2025503661A publication Critical patent/JP2025503661A/ja
Publication of JP2025503661A5 publication Critical patent/JP2025503661A5/ja
Pending legal-status Critical Current

Links

JP2024541657A 2022-01-10 2023-01-09 Ｈｓｅｔインヒビターとしての置換ヘテロ環 Pending JP2025503661A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22150667.8 2022-01-10
EP22150667 2022-01-10
PCT/EP2023/050255 WO2023131690A1 (en) 2022-01-10 2023-01-09 Substituted heterocycles as hset inhibitors

Publications (2)

Publication Number Publication Date
JP2025503661A JP2025503661A (ja) 2025-02-04
JP2025503661A5 true JP2025503661A5 (https=) 2026-01-19

Family

ID=79288014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541657A Pending JP2025503661A (ja) 2022-01-10 2023-01-09 Ｈｓｅｔインヒビターとしての置換ヘテロ環

Country Status (8)

Country Link
US (1) US20250084074A1 (https=)
EP (1) EP4463444A1 (https=)
JP (1) JP2025503661A (https=)
CN (1) CN119421877A (https=)
AU (1) AU2023205435A1 (https=)
CA (1) CA3247641A1 (https=)
IL (1) IL314200A (https=)
WO (1) WO2023131690A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR130226A1 (es) * 2022-08-23 2024-11-20 Merck Patent Gmbh Biciclos sustituidos como inhibidores de hset

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207554A (en) 1972-08-04 1980-06-10 Med-El Inc. Method and apparatus for automated classification and analysis of cells
US4125828A (en) 1972-08-04 1978-11-14 Med-El Inc. Method and apparatus for automated classification and analysis of cells
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
US7250415B2 (en) * 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
CA2725911A1 (en) 2008-05-30 2009-12-23 Dana-Farber Cancer Institute, Inc. Methods of treating a meiotic kinesin-associated disease
US20150309031A2 (en) 2013-12-05 2015-10-29 Novazoi Theranostics Compositions and methods for prognosis and treatment of cancer
US9783510B2 (en) * 2014-08-22 2017-10-10 Vanderbilt University Small molecule mediated transcriptional induction of E-cadherin

Similar Documents

Publication Publication Date Title
JP7326622B2 (ja) Ｅｒｋ阻害剤としてのスピロ系化合物およびその使用
KR101960129B1 (ko) 피롤로벤조디아제핀
TW202144338A (zh) 嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用
JP2024524524A (ja) 窒素含有複素環化合物、その製造方法、中間体及び使用
ES2618007T3 (es) Nuevos compuestos de pirrolopirimidina como inhibidores de proteína cinasas
WO2019233447A1 (en) Compounds as nuclear transport modulators and uses thereof
JP7088906B2 (ja) Ｆｇｆｒ４阻害剤並びにその製造方法及び使用
JP2017519754A5 (https=)
ES2714100T3 (es) Compuestos de quinolina fusionados como inhibidores de mTor, pi3k
WO2009047298A2 (en) Dimers of harmol or of its derivatives and uses thereof
JP2025503661A5 (https=)
JP2018520167A (ja) ＰＩ３Ｋ／ｍＴＯＲ阻害剤としての溶融キノリン化合物
JP2017137323A (ja) 新規抗がん剤
US10351586B2 (en) Cytidine derivative dimers and applications thereof
JP6450678B2 (ja) 新規な化合物およびその使用
JP2005531563A5 (https=)
CN101671301A (zh) 杂环取代的二苯脲类衍生物及其用途
JP5701387B2 (ja) ベルバミンのジカルボキシミド誘導体、その調製方法及び使用
US10738049B2 (en) N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-D]pyrimidin-1-YL]-phenyl}-cyclopropanecarboxamide dimethyl sulfoxide solvate as an MEK1/2 inhibitor
US10711002B2 (en) Purine compounds and method for the treatment of cancer
US20170368177A1 (en) Novel peg derivative
EP3525795A1 (en) Phenothiazine derivatives and methods of use thereof
CN105384699B (zh) 一种新型喹唑啉衍生物lu1501及其制备方法和应用
US10507212B2 (en) Method for use of homopiperazinium compounds in the treatment of cancer
WO2026096781A1 (en) Pi3k inhibitors, compositions, and uses thereof